Viral vector-based systems are undergoing a major expansion to clinical applications, with several therapies being approved by the US Food and Drug Administration for treating genetic diseases and cancers. As a land-grant university, the University of Minnesota’s clear mission is to bring scientific advancement back to patients in Minnesota and worldwide. The Viral Vector Core Consortium Workshop will provide a forum for academic and industry partners to discuss the major challenges of bringing novel genetic therapeutics from bench-to-bedside. This Consortium will make major ongoing contributions to the development and promotion of novel biological treatments.
Keynote Speakers:
- H. Trent Spencer, PhD, Professor, Department of Pediatrics, Emory University, School of Medicine, Director, Cell and Gene Therapy, Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta, Atlanta, GA
- Junhae Suh, PhD, Vice President, Gene Therapy Accelerator Unit, Biogen, Cambridge, MA
Speakers:
- George Aslanidi, PhD, Professor, The Hormel Institute, University of Minnesota
- Christina Pacak, PhD, Assistant Professor, Neurology, Medical School, University of Minnesota
- Tom Yezzi, MSc, Chief Executive Officer, Nu-Tek BioSciences, Austin, MN
Panelists:
- R. Scott McIvor, PhD, Professor of Genetics, Cell Biology and Development, Department of Genetics, College of Biological Sciences, University of Minnesota
- Masato Yamamoto, MD, PhD, Professor, Surgery, Eugene C. and Gail V. Sit Chair in Pancreatic and Gastrointestinal Cancer Research, Vice-Chair of Surgical Science, Medical School, University of Minnesota
- Sandra Wells, PhD, Director, Office of Discovery and Translation, Clinical and Translational Science Institute, University of Minnesota
- Christina Pacak, PhD, Assistant Professor, Neurology, Medical School, University of Minnesota
Sponsors
 |
 |
 |
 |